Detalles de la búsqueda
1.
Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML.
Blood
; 141(9): 1023-1035, 2023 03 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35981498
2.
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.
Blood
; 140(10): 1104-1118, 2022 09 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35878001
3.
CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.
Cancer Immunol Immunother
; 72(7): 2499-2512, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37041225
4.
Correction to: CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.
Cancer Immunol Immunother
; 72(7): 2513-2514, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37154851
5.
Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia.
Nat Biotechnol
; 41(11): 1618-1632, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36914885
6.
The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression.
Front Immunol
; 12: 608625, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33790890
7.
A modular and controllable T cell therapy platform for acute myeloid leukemia.
Leukemia
; 35(8): 2243-2257, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33414484
Resultados
1 -
7
de 7
1
Próxima >
>>